Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CRLBF NASDAQ:LKFT NASDAQ:NRIX NASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRLBFCresco Labs$0.92-4.5%$0.96$0.43▼$2.30$460.93M1.59704,078 shs438,410 shsLKFTLakefront Biotherapeutics American Depositary Shares$28.35+0.1%$28.70$26.42▼$37.78$1.87B0.25154,858 shs117,842 shsNRIXNurix Therapeutics$17.76+0.5%$16.22$8.19▼$22.50$1.84B1.871.00 million shs1.16 million shsOCULOcular Therapeutix$9.01-1.5%$8.80$6.23▼$16.44$1.97B0.932.77 million shs2.40 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRLBFCresco Labs0.00%+6.59%-15.89%-7.39%+36.84%LKFTLakefront Biotherapeutics American Depositary Shares0.00%+3.13%+1.87%-15.78%-2.68%NRIXNurix Therapeutics0.00%+1.49%+6.35%+11.21%+76.89%OCULOcular Therapeutix0.00%+9.48%-3.84%+0.78%+14.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRLBFCresco Labs$0.92-4.5%$0.96$0.43▼$2.30$460.93M1.59704,078 shs438,410 shsLKFTLakefront Biotherapeutics American Depositary Shares$28.35+0.1%$28.70$26.42▼$37.78$1.87B0.25154,858 shs117,842 shsNRIXNurix Therapeutics$17.76+0.5%$16.22$8.19▼$22.50$1.84B1.871.00 million shs1.16 million shsOCULOcular Therapeutix$9.01-1.5%$8.80$6.23▼$16.44$1.97B0.932.77 million shs2.40 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRLBFCresco Labs0.00%+6.59%-15.89%-7.39%+36.84%LKFTLakefront Biotherapeutics American Depositary Shares0.00%+3.13%+1.87%-15.78%-2.68%NRIXNurix Therapeutics0.00%+1.49%+6.35%+11.21%+76.89%OCULOcular Therapeutix0.00%+9.48%-3.84%+0.78%+14.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRLBFCresco Labs 3.00BuyN/AN/ALKFTLakefront Biotherapeutics American Depositary Shares 2.00Hold$36.5028.75% UpsideNRIXNurix Therapeutics 2.93Moderate Buy$30.4671.52% UpsideOCULOcular Therapeutix 2.79Moderate Buy$23.78163.90% UpsideCurrent Analyst Ratings BreakdownLatest CRLBF, LKFT, OCUL, and NRIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026LKFTLakefront Biotherapeutics American Depositary Shares Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/18/2026NRIXNurix Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.005/8/2026LKFTLakefront Biotherapeutics American Depositary Shares Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/6/2026OCULOcular Therapeutix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$30.005/5/2026OCULOcular Therapeutix Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.004/27/2026NRIXNurix Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.004/23/2026NRIXNurix Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$26.004/21/2026NRIXNurix Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026OCULOcular Therapeutix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026OCULOcular Therapeutix HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.004/10/2026NRIXNurix Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.00(Data available from 5/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRLBFCresco Labs$655.85M0.70$0.04 per share23.81$0.49 per share1.87LKFTLakefront Biotherapeutics American Depositary Shares$1.26B1.49$0.73 per share39.05$57.78 per share0.49NRIXNurix Therapeutics$83.98M21.87N/AN/A$5.29 per share3.36OCULOcular Therapeutix$51.95M37.98N/AN/A$2.66 per share3.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRLBFCresco Labs-$135.41M-$0.39N/AN/AN/A-20.90%-17.98%-4.29%8/6/2026 (Estimated)LKFTLakefront Biotherapeutics American Depositary Shares$363.05M-$1.41N/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)NRIXNurix Therapeutics-$264.46M-$3.16N/AN/AN/A-411.37%-64.21%-48.44%7/9/2026 (Estimated)OCULOcular Therapeutix-$265.94M-$1.46N/AN/AN/A-558.24%-64.28%-48.15%8/4/2026 (Estimated)Latest CRLBF, LKFT, OCUL, and NRIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026CRLBFCresco Labs-$0.03-$0.04-$0.01-$0.04$148.58 million$151.33 million5/6/2026Q1 2026LKFTLakefront Biotherapeutics American Depositary Shares-$1.27$0.25+$1.52$0.25$11.26 million$7.50 million4/8/2026Q1 2026NRIXNurix Therapeutics-$0.76-$0.79-$0.03-$0.79$14.25 million$6.25 million3/5/2026Q4 2025CRLBFCresco Labs-$0.02-$0.02N/A$0.21$160.87 million$164.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRLBFCresco LabsN/AN/AN/AN/AN/ALKFTLakefront Biotherapeutics American Depositary SharesN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRLBFCresco Labs1.782.511.41LKFTLakefront Biotherapeutics American Depositary SharesN/A30.4830.30NRIXNurix TherapeuticsN/A6.016.01OCULOcular Therapeutix0.1214.8114.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRLBFCresco Labs0.05%LKFTLakefront Biotherapeutics American Depositary Shares32.46%NRIXNurix TherapeuticsN/AOCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipCRLBFCresco LabsN/ALKFTLakefront Biotherapeutics American Depositary Shares2.91%NRIXNurix Therapeutics6.70%OCULOcular Therapeutix2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRLBFCresco Labs2,900502.76 millionN/ANot OptionableLKFTLakefront Biotherapeutics American Depositary Shares1,31065.90 million63.98 millionOptionableNRIXNurix Therapeutics300103.41 million96.48 millionOptionableOCULOcular Therapeutix230218.96 million213.92 millionOptionableCRLBF, LKFT, OCUL, and NRIX HeadlinesRecent News About These CompaniesOcular Therapeutix (NASDAQ:OCUL) Insider Sells $15,235.60 in StockMay 29 at 8:47 AM | insidertrades.comOcular Therapeutix Shrinking The Burden Of BlindnessMay 28 at 11:21 AM | bloomberg.comAcuta Capital Sells 56% of Ocular Therapeutix Shares in Q1May 27, 2026 | finance.yahoo.comOcular Therapeutix Inc (OCUL)May 24, 2026 | investing.comWhat This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for InvestorsMay 20, 2026 | finance.yahoo.comOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 15, 2026 | globenewswire.comOcular Therapeutix, Inc. $OCUL Shares Bought by Empire Life Investments Inc.May 13, 2026 | marketbeat.comOcular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comDole posts downbeat Q1 earnings, joins Ocular Therapeutix and other big stocks moving lower in Monday's pre-market sessionMay 11, 2026 | msn.comOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2026 | globenewswire.comOcular: SOL-1 Success Is Real, But Adoption Risks Keep Me At HoldMay 8, 2026 | seekingalpha.comOcular Therapeutix Starts SOL-X Trial As AXPAXLI Data And Valuation DivergeMay 8, 2026 | finance.yahoo.comHC Wainwright Has Negative Outlook for OCUL Q2 EarningsMay 8, 2026 | marketbeat.comBrokers Set Expectations for OCUL FY2027 EarningsMay 7, 2026 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from Needham & Company LLCMay 7, 2026 | marketbeat.comOcular Therapeutix (OCUL) Gets a Buy from H.C. WainwrightMay 6, 2026 | theglobeandmail.comWhy Ocular Therapeutix (OCUL) Stock Is NosedivingMay 6, 2026 | theglobeandmail.comAssessing Ocular Therapeutix (OCUL) Valuation As Axpaxli Expectations Meet Volatile ReturnsMay 6, 2026 | finance.yahoo.comOcular Therapeutix (NASDAQ:OCUL) Receives "Outperform" Rating from Royal Bank Of CanadaMay 6, 2026 | marketbeat.comOcular Therapeutix outlines SOL-R top line data in Q1 2027 while advancing AXPAXLI NDA planMay 5, 2026 | msn.comOcular Therapeutix Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRLBF, LKFT, OCUL, and NRIX Company DescriptionsCresco Labs OTCMKTS:CRLBF$0.92 -0.04 (-4.48%) As of 05/29/2026 03:59 PM EasternCresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT$28.35 +0.03 (+0.11%) As of 05/29/2026 04:00 PM EasternGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Nurix Therapeutics NASDAQ:NRIX$17.76 +0.09 (+0.51%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$17.76 0.00 (0.00%) As of 05/29/2026 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Ocular Therapeutix NASDAQ:OCUL$9.01 -0.14 (-1.53%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$9.04 +0.03 (+0.33%) As of 05/29/2026 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds These 3 Software Stocks Are Buying Back Shares Hand Over Fist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
